TY - JOUR
T1 - Down regulation of RhoC by microRNA-138 results in de-activation of FAK, Src and Erk1/2 signaling pathway in head and neck squamous cell carcinoma
AU - Islam, Mozaffarul
AU - Datta, Jharna
AU - Lang, James C.
AU - Teknos, Theodoros N.
N1 - Funding Information:
This study was supported by the Ohio State University Comprehensive Cancer Center and Slomin Family Foundation (FL, USA) to Ted Teknos. The authors thank Dr. N.S. Mahfooz, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy Center for Microbial Interface Biology at the Ohio State University for critical reading of the manuscript and help in miR-database search. Thanks are also due to Maria Deri for revision assistance.
PY - 2014/5
Y1 - 2014/5
N2 - Objective RhoC a pro-metastatic oncogene is constitutively active in many head and neck squamous cell carcinomas. MicroRNA-138 which possesses a documented tumor suppressor function can bind to the 3′UTR of RhoC mRNA and inhibit its activity. We hypothesize that miR-138 can inhibit the function of RhoC and consequently the activation of downstream target molecules involve in the signaling cascade. For this reason we investigated the role of miR-138 in HNSCC. Methods In vitro studies were carried out to evaluate the role of miR-138 in HNSCC cell lines and in primary tumors obtained from HNSCC patients. Real time RT-PCR, Western blot, cell motility, invasion and colony formation assays were performed according to standard procedures. Results Data obtained by G-LISA and real time PCR shows an inverse correlation between RhoC expression and miR-138 in HNSCC cell lines. Additionally, we obtained a similar pattern of RhoC and miR-138 expression in primary tumors from HNSCC patients. Over expression of miR-138 in HNSCC lines showed down regulation of RhoC, as well as a decrease in cell motility, invasion colony and stress fiber formation. Furthermore, a significant down regulation was observed for FAK, Src and Erk1/2 upon miR-138 overexpression. Conclusion These findings strongly suggest that the inhibition of RhoC can be achieved by over expressing miR-138, which further attenuates the downstream signaling cascade leading to cancer progression and survival. Moreover, this study for the first time shows that down regulation of FAK, Src and Erk1/2 by miR-138 overexpression is due to inhibition of RhoC in HNSCC.
AB - Objective RhoC a pro-metastatic oncogene is constitutively active in many head and neck squamous cell carcinomas. MicroRNA-138 which possesses a documented tumor suppressor function can bind to the 3′UTR of RhoC mRNA and inhibit its activity. We hypothesize that miR-138 can inhibit the function of RhoC and consequently the activation of downstream target molecules involve in the signaling cascade. For this reason we investigated the role of miR-138 in HNSCC. Methods In vitro studies were carried out to evaluate the role of miR-138 in HNSCC cell lines and in primary tumors obtained from HNSCC patients. Real time RT-PCR, Western blot, cell motility, invasion and colony formation assays were performed according to standard procedures. Results Data obtained by G-LISA and real time PCR shows an inverse correlation between RhoC expression and miR-138 in HNSCC cell lines. Additionally, we obtained a similar pattern of RhoC and miR-138 expression in primary tumors from HNSCC patients. Over expression of miR-138 in HNSCC lines showed down regulation of RhoC, as well as a decrease in cell motility, invasion colony and stress fiber formation. Furthermore, a significant down regulation was observed for FAK, Src and Erk1/2 upon miR-138 overexpression. Conclusion These findings strongly suggest that the inhibition of RhoC can be achieved by over expressing miR-138, which further attenuates the downstream signaling cascade leading to cancer progression and survival. Moreover, this study for the first time shows that down regulation of FAK, Src and Erk1/2 by miR-138 overexpression is due to inhibition of RhoC in HNSCC.
KW - FAK
KW - Head and neck cancer
KW - RhoC
KW - Src
KW - miR-138
UR - https://www.scopus.com/pages/publications/84899060290
U2 - 10.1016/j.oraloncology.2014.01.014
DO - 10.1016/j.oraloncology.2014.01.014
M3 - Article
C2 - 24565984
AN - SCOPUS:84899060290
SN - 1368-8375
VL - 50
SP - 448
EP - 456
JO - Oral Oncology
JF - Oral Oncology
IS - 5
ER -